INS and type 1 diabetes mellitus: In a recent analysis of ADJUNCT ONE and ADJUNCT TWO, two randomized controlled phase 3 trials in T1DM, treatment with daily liraglutide 1.8 mg over 52 weeks was associated with a significant reduction in the placebo-adjusted HbA1c, body weight, and insulin dose (ADJUNCT ONE: −0.30%, −5.0 kg, and −12%; ADJUNCT TWO: −0.35%, −4.8 kg, and −10%, respectively) [6].